Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors.
D000818:Animals; D000917:Antibody Formation; D001102:Arbovirus Infections / Q000276:immunology*; D001921:Brain / Q000473:pathology; D046508:Culture Techniques; D003520:Cyclophosphamide / Q000494:pharmacology*; D004660:Encephalitis / Q000276:immunology*; D005455:Fluorescent Antibody Technique; D007116:Immunization, Passive; D007165:Immunosuppression Therapy; D007372:Interferons / Q000096:biosynthesis; D007739:L Cells; D007928:Lethal Dose 50; D008212:Lymphocyte Depletion; D008214:Lymphocytes / Q000276:immunology; D008217:Lymphocytic choriomeningitis virus / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D013116:Spinal Cord / Q000473:pathology; D013154:Spleen / Q000166:cytology; D013601:T-Lymphocytes / Q000276:immunology; D014721:Vesicular stomatitis Indiana virus / Q000276:immunology; D014776:Virus Cultivation; D014901:West Nile Fever / Q000276:immunology*; D014902:West Nile virus / Q000276:immunology*
D003520:Cyclophosphamide; D007372:Interferons